Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BUMEX vs ATROMID-S
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Bumetanide inhibits the Na-K-2Cl symporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased diuresis.
Inhibits hepatic triglyceride synthesis and increases lipoprotein lipase activity, leading to reduced VLDL and triglycerides.
Edema associated with congestive heart failure,Edema associated with hepatic cirrhosis,Edema associated with renal disease including nephrotic syndrome
Type III hyperlipoproteinemia,Hypertriglyceridemia (Fredrickson types IV and V) not responsive to diet
0.5-2 mg orally once daily; if inadequate response, may increase to 2-4 mg once daily or twice daily. Maximum 10 mg/day. IV: 0.5-1 mg IV over 1-2 minutes; may repeat every 2-3 hours up to 10 mg/day.
500 mg to 1 g orally twice daily. Maximum dose 2 g/day.
Terminal elimination half-life: 1.5–2 hours in normal renal function; prolonged to 2.5–4 hours in severe renal impairment (Cr Cl <20 m L/min).
Terminal elimination half-life is 6-8 hours in patients with normal renal function; may be prolonged to 12-24 hours in renal impairment.
Primarily metabolized by the liver via cytochrome P450 enzymes, including CYP2C9 and CYP3A4.
Hepatic via glucuronidation and oxidation; major metabolite is clofibric acid.
Renal: 80% as unchanged drug; biliary/fecal: 15% as metabolites; total renal elimination accounts for ~85% of clearance.
Primarily renal excretion as glucuronide conjugates; approximately 60-70% of the dose is excreted in urine, 20-30% in feces via biliary elimination.
Bumetanide is 94–96% bound to plasma proteins (primarily albumin).
>95% bound to plasma proteins, primarily albumin.
0.15–0.22 L/kg; indicates primarily extracellular distribution.
0.11-0.14 L/kg; low Vd indicates limited extravascular distribution, consistent with high protein binding.
Oral bioavailability: 80–100% (mean ~95%).
Oral: approximately 60-70% due to first-pass metabolism; administered as clofibrate (prodrug) which is hydrolyzed to active clofibric acid.
e GFR <20 m L/min/1.73 m²: Avoid loop diuretics; consider alternative. No adjustment for mild to moderate renal impairment, but monitor response. In severe renal failure, may require higher doses due to reduced tubular secretion.
GFR 30-59 m L/min: 500 mg twice daily. GFR 15-29 m L/min: 250 mg twice daily. GFR <15 m L/min: avoid use.
Child-Pugh Class B or C: Reduce initial dose by 50% due to impaired metabolism and increased risk of volume depletion. Titrate cautiously.
Child-Pugh Class B or C: avoid use or reduce dose by at least 50%; not recommended in severe hepatic impairment.
Infants/Children: Oral: 0.015-0.1 mg/kg/dose once daily; maximum 10 mg/day. IV/IM: 0.015-0.1 mg/kg/dose every 12-24 hours; maximum 0.5 mg/kg/dose. Neonates: 0.01-0.05 mg/kg/dose every 24-48 hours.
Not recommended; safety and efficacy not established in pediatric patients.
Start at 0.5 mg orally once daily; increase cautiously due to enhanced pharmacodynamic effects and higher risk of electrolyte disturbances, volume depletion, and ototoxicity. Monitor renal function and electrolytes closely.
Start at lower end of dosing range (500 mg twice daily). Monitor renal function; adjust dose based on GFR.
Bumetanide is a potent diuretic; if given in excessive amounts, can lead to profound diuresis with water and electrolyte depletion. Therefore, careful medical supervision is required, and dose and dosage schedule must be adjusted to individual patient's needs.
None
Electrolyte depletion (hypokalemia, hyponatremia, hypochloremia),Dehydration and hypovolemia,Ototoxicity (especially with rapid injection or in renal impairment),Excessive diuresis causing hypotension and thromboembolic events,May increase serum uric acid levels and precipitate gout,Risk of hypokalemia in patients with cirrhosis and ascites
Hepatotoxicity,Cholelithiasis,Renal impairment dose adjustment,Rhabdomyolysis risk with statins,Malignancy risk (hepatic, GI)
Anuria,Hepatic coma or severe electrolyte depletion until condition is corrected,Hypersensitivity to bumetanide or sulfonamides (cross-sensitivity possible)
Hypersensitivity to clofibrate,Active liver disease,Severe renal dysfunction,Primary biliary cirrhosis,Pregnancy
Avoid excessive salt intake; no specific food interactions reported. Avoid licorice as it may worsen hypokalemia. Grapefruit juice may increase bumetanide levels; use caution.
High-fat meals may reduce absorption; consistent timing of administration with food is recommended. Grapefruit juice may increase drug levels; avoid excessive intake. Alcohol may exacerbate hepatotoxicity.
Bumetanide (BUMEX) is a loop diuretic classified as FDA Pregnancy Category C. Animal studies have shown embryocidal effects and delayed ossification at high doses. Human data are limited; no well-controlled studies exist. First trimester: theoretical risk based on animal data; avoid unless essential. Second/third trimesters: may cause maternal hypovolemia, decreased placental perfusion, and fetal oliguria; use only if clearly needed and monitor amniotic fluid volume. Neonatal risks include electrolyte imbalances and ototoxicity if used close to delivery.
FDA Pregnancy Category C. First trimester: Potential for teratogenicity based on animal studies showing skeletal and visceral anomalies. Human data limited; use only if benefit outweighs risk. Second and third trimesters: May cause fetal harm due to placental transfer and potential for reduced fetal growth.
Bumetanide is excreted into human milk in low concentrations. The milk-to-plasma (M/P) ratio is approximately 0.05-0.10. Based on limited data, amounts ingested by breastfed infants are unlikely to cause adverse effects. However, due to potential risk of hypersensitivity, electrolyte disturbances, or diuresis in the infant, caution is advised, especially in premature or renal-impaired infants. Alternative diuretics with more safety data may be preferred.
Excreted into breast milk in low amounts; M/P ratio not established. Due to potential for serious adverse effects in infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
Pregnancy may alter bumetanide pharmacokinetics due to increased plasma volume, renal blood flow, and glomerular filtration rate. Higher doses may be required to achieve the same diuretic effect. However, no standard dose adjustment guidelines exist; use the lowest effective dose and titrate based on clinical response, monitoring for electrolyte disturbances and volume depletion. In severe preeclampsia or renal impairment, dose may need reduction. Close therapeutic drug monitoring is not routinely available; clinical monitoring of diuresis and electrolytes guides dosing.
No specific dosing adjustments recommended due to lack of data. However, pharmacokinetic changes in pregnancy (increased volume of distribution, altered metabolism) may necessitate careful monitoring and empiric dose adjustments based on clinical response and adverse effects.
Bumetanide is a loop diuretic approximately 40 times more potent than furosemide; onset of diuresis within 30-60 minutes after oral administration. Monitor for ototoxicity, especially with rapid IV administration or concurrent use of other ototoxic drugs. Hypokalemia is a common adverse effect; consider potassium supplementation or concurrent use of potassium-sparing diuretics. Contraindicated in anuria, hepatic coma, and severe electrolyte depletion. May cause hyperuricemia and precipitate gout attacks.
ATROMID-S (clofibrate) is a fibric acid derivative primarily indicated for hyperlipidemia but its use is now limited due to increased non-cardiovascular mortality and cholelithiasis risk. Monitor liver function and prothrombin time (potentiates warfarin). Not first-line; consider statins or fibrates like fenofibrate.
Take this medication exactly as prescribed, typically once daily in the morning to avoid nighttime urination.,Avoid sudden position changes to prevent dizziness from low blood pressure.,Do not consume grapefruit juice or alcohol while taking this drug.,Monitor for signs of electrolyte imbalance: muscle cramps, weakness, irregular heartbeat, or confusion.,Weigh yourself daily and report rapid weight gain or loss to your healthcare provider.
Take with meals to reduce gastrointestinal upset.,Report unexplained muscle pain, tenderness, or weakness; may indicate myopathy.,Avoid alcohol as it may increase liver enzyme elevations.,Notify your doctor if you develop gallstones symptoms (e.g., right upper abdominal pain, nausea).,Use effective contraception as clofibrate may cause fetal harm.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BUMEX vs ATROMID-S, answered by our medical review team.
BUMEX is a Loop Diuretic that works by Bumetanide inhibits the Na-K-2Cl symporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased diuresis.. ATROMID-S is a Antilipemic Agent that works by Inhibits hepatic triglyceride synthesis and increases lipoprotein lipase activity, leading to reduced VLDL and triglycerides.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BUMEX and ATROMID-S depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BUMEX is: 0.5-2 mg orally once daily; if inadequate response, may increase to 2-4 mg once daily or twice daily. Maximum 10 mg/day. IV: 0.5-1 mg IV over 1-2 minutes; may repeat every 2-3 hours up to 10 mg/day.. The standard adult dose of ATROMID-S is: 500 mg to 1 g orally twice daily. Maximum dose 2 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BUMEX and ATROMID-S in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BUMEX is classified as Category C. Bumetanide (BUMEX) is a loop diuretic classified as FDA Pregnancy Category C. Animal studies have shown embryocidal effects and delayed ossification at high doses. Human data are l. ATROMID-S is classified as Category C. FDA Pregnancy Category C. First trimester: Potential for teratogenicity based on animal studies showing skeletal and visceral anomalies. Human data limited; use only if benefit out. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.